Business News • PR NewsWire • Phase 2a Clinical Study Data of AJM300, Oral alpha 4 Integrin Antagonist, Will Be Presented in Digestive Disease Week 2014

Phase 2a Clinical Study Data of AJM300, Oral alpha 4 Integrin Antagonist, Will Be Presented in Digestive Disease Week 2014

Phase 2a Clinical Study Data of AJM300, Oral alpha 4 Integrin Antagonist, Will Be Presented in Digestive Disease Week 2014

TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 -...

View More : http://www.prnewswire.com/news-releases/phase-2a-clinical-study-data-of-ajm300-oral-alpha-4-integrin-antagonist-will-be-...

Releted News by prnewswire

Syngenta First quarter 2014: sales $4.7 billion

Datos del estudio clínico del antagonista oral alpha 4 Integrin en la Semana de las Enfermedades Digestivas de 2014